# Highlights of This Issue 2503

## SPECIAL FEATURES

### CCR Translations

- **2505 Minimal Residual Disease in Breast Cancer: In Blood Veritas**  
  Giulia Siravegna and Alberto Bardelli  
  See related article, p. 2643

### Molecular Pathways

- **2508 Molecular Pathways: Preclinical Models and Clinical Trials with Metformin in Breast Cancer**  
  Alastair M. Thompson
- **2516 Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF–MEK–ERK Pathway in Cancer**  
  Gary L. Johnson, Timothy J. Stuhlmiller, Steven P. Angus, Jon S. Zawistowski, and Lee M. Graves

### CCR Focus

- **2524 The Language of Pharmacodynamics**  
  Susan E. Bates
- **2525 Pharmacologic Biomarkers in the Development of Stratified Cancer Medicine**  
  William Douglas Figg and David R. Newell
- **2530 Using Pharmacogene Polymorphism Panels to Detect Germline Pharmacodynamic Markers in Oncology**  
  Daniel L. Hertz and Howard L. McLeod
- **2541 Genome-Wide Association Study: A Useful Tool to Identify Common Genetic Variants Associated with Drug Toxicity and Efficacy in Cancer Pharmacogenomics**  
  Siew-Kee Low, Atsushi Takahashi, Taisei Mushiroda, and Michiaki Kubo
- **2553 Circulating Tumor Cells: A Multifunctional Biomarker**  
  Timothy A. Yap, David Lorente, Aurelius Omlin, David Olmos, and Johann S. de Bono

### HUMAN CANCER BIOLOGY

- **2595 FOXM1 Promotes the Warburg Effect and Pancreatic Cancer Progression via Transactivation of LDHA Expression**  
  Jiujie Cui, Min Shi, Dacheng Xie, Daoyan Wei, Zhiliang Jia, Shaojiang Zheng, Yong Gao, Suyun Huang, and Keping Xie
- **2607 Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration**  
  Edmund K. Bartlett, Patricia A. Fetsch, Armando C. Filie, Andrea Abati, Seth M. Steinberg, John R. Wunderlich, Donald E. White, Daniel J. Stephens, Francesco M. Marincola, Steven A. Rosenberg, and Udai S. Kammula
- **2617 miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression**  
  Xuanryu Chen, Xuegang Wang, Anming Ruan, Weiwel Han, Yan Zhao, Xing Lu, Pei Xiao, Hangchuan Shi, Rong Wang, Li Chen, Shaoyong Chen, Quansheng Du, Hongmei Yang, and Xiaoping Zhang
- **2631 Regulation of Colorectal Carcinoma Stemness, Growth, and Metastasis by an miR-200c-Sox2–Negative Feedback Loop Mechanism**  
  Yan-Xia Lu, Li Yuan, Xiao-Lei Xue, Min Zhou, Yan Liu, Chao Zhang, Jing-Ping Li, Lin Zheng, MinHong, and Xue-Nong Li
Table of Contents

2761  A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response
Rita A. Busuttil, Joshy George, Richard W. Tothill, Kylie loculano, Adam Kowalczyk, Catherine Mitchell, Stephen Lade, Patrick Tan, Izhak Haviv, and Alex Boussioutas

2773  In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
Kurt A. Schalper, Vamsidhar Velcheti, Daniel Carvajal, Hallie Wimberly, Jason Brown, Lajos Pusztai, and David L. Rimm

2783  Population Pharmacokinetics of Bevacizumab in Children with Osteosarcoma: Implications for Dosing

2793  A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases
Josep Tabernero, Maria Elena Elez, Maria Herranz, Isabel Rico, Ludmila Prudkin, Jordi Andreu, Jose Mateos, Maria Josep Carreras, May Han, James Gifford, Marc Credi, Wei Yin, Shefali Agarwal, Philip Komarnitsky, and Jose Baselga

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

2803  Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff
Renata Duchnowska, Jeff Sperinde, Ahmed Chenna, Mojgan Haddad, Agnes Paquet, Yolanda Lie, Jodi M. Weidler, Weidong Huang, John Winslow, Tomasz Jankowski, Bogumila Czartoryska-Arhkowicz, Piotr J. Wysocki, Malgorzata Foszczyńska-Kłoda, Barbara Radecka, Maria M. Litwiniuk, Jolanta Żok, Michal Wiśniewski, Dorota Zuziak, Wojciech Biernat, and Jacek Jassem

ABOUT THE COVER

The cover shows a brain section from a mouse injected with a brain seeking variant of the human breast cancer cell line MDA-MB-231. Immunohistochemical staining indicates a lack of MGMT expression in the tumor cells. Tissue was stained with anti-MGMT antibody and counterstained with hematoxylin and eosin. For details, see the article by Palmieri and colleagues on page 2727 of this issue.

AC icon indicates Author Choice
CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org
For more information please visit www.aacrjournals.org